Literature DB >> 8285306

Topical pharmacotherapy for allergic rhinitis: nedocromil.

R L Mabry1.   

Abstract

Nedocromil sodium is a mast-cell stabilizer that prevents or ablates both the acute and late phases of the allergic response. It is an antiinflammatory agent that is not a steroid. It is more potent than the currently available mast-cell stabilizer, cromolyn, and maintenance therapy may be possible at less frequent intervals than the initially recommended regimen of 4 times daily. Nedocromil for pulmonary administration is currently available. The nasal form has undergone clinical trials but has not yet been released in the United States.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8285306      PMCID： PMC7135241          DOI： 10.1016/0196-0709(93)90110-s

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN： 0196-0709            Impact factor:   1.808


  13 in total

Review 1.  Topical pharmacotherapy for allergic rhinitis: new agents.

Authors:  R L Mabry
Journal:  South Med J       Date:  1992-02       Impact factor: 0.954

2.  Effect of inhaled preservatives on asthmatic subjects. I. Sodium metabisulfite.

Authors:  W Wright; Y G Zhang; C M Salome; A J Woolcock
Journal:  Am Rev Respir Dis       Date:  1990-06

Review 3.  The pharmacology of nedocromil sodium.

Authors:  R P Eady
Journal:  Eur J Respir Dis Suppl       Date:  1986

4.  The effect of nedocromil sodium on nasal provocation with allergen.

Authors:  O J Corrado; E Gomez; D L Baldwin; J E Clague; R J Davies
Journal:  J Allergy Clin Immunol       Date:  1987-08       Impact factor: 10.793

5.  A multicenter trial of nedocromil sodium, 1% nasal solution, compared with cromolyn sodium and placebo in ragweed seasonal allergic rhinitis.

Authors:  D E Schuller; J E Selcow; T H Joos; P J Hannaway; S R Hirsch; H J Schwartz; W V Filley; J N Fink
Journal:  J Allergy Clin Immunol       Date:  1990-10       Impact factor: 10.793

6.  A double-blind multicenter group comparative study of the efficacy and safety of nedocromil sodium in the management of asthma. North American Tilade Study Group.

Authors: 
Journal:  Chest       Date:  1990-06       Impact factor: 9.410

7.  A double-blind group comparative study of nedocromil sodium in the treatment of seasonal allergic rhinitis.

Authors:  P Bellioni; F Salvinelli; F Patalano; F Ruggieri
Journal:  Rhinology       Date:  1988-12       Impact factor: 3.681

8.  Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mast cells.

Authors:  E Wells; C G Jackson; S T Harper; J Mann; R P Eady
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

9.  A double-blind, placebo-controlled study to assess the efficacy of nedocromil sodium in the management of childhood grass-pollen asthma.

Authors:  L Businco; A Cantani; A Di Fazio; L Bernardini
Journal:  Clin Exp Allergy       Date:  1990-11       Impact factor: 5.018

10.  The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers.

Authors:  G I Barrow; P G Higgins; W al-Nakib; A P Smith; R B Wenham; D A Tyrrell
Journal:  Clin Exp Allergy       Date:  1990-01       Impact factor: 5.018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.